Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961815 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study of Brazikumab in Crohn's Disease
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT03961815 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 18 participants.
The verdict
NCT03961815, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002 (Legacy #3150-303-008). This will permit long-term observation of safety in these participants with brazikumab.
Interventions
- DRUG Brazikumab Induction Dose
- DRUG Brazikumab Maintenance Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2023-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961815
The ClinicalTrials.gov registry entry for NCT03961815 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brazikumab Induction Dose is the first listed.
NCT03961815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961815 about?
NCT03961815 is a clinical study titled "Open-label Extension Study of Brazikumab in Crohn's Disease". The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002 (Legacy #3150-303-008). This will permit long-term observation of safety in these participants with brazikumab.
What is the current status of trial NCT03961815?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2020-01-06. Estimated completion is 2023-09-19.
What interventions are being tested in trial NCT03961815?
The interventions under investigation include: Brazikumab Induction Dose (DRUG), Brazikumab Maintenance Dose (DRUG).
Who is sponsoring clinical trial NCT03961815?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.